CYR61 confers chemoresistance by upregulating survivin expression in triple-negative breast cancer

被引:2
|
作者
Kim, Hyungjoo [1 ]
Son, Seogho [1 ]
Ko, Yunhyo [1 ]
Lim, Hogeun [1 ]
Lee, Joohyung [1 ]
Lee, Kyung-Min [1 ,2 ,3 ]
Shin, Incheol [1 ,2 ,3 ]
机构
[1] Hanyang Univ, Dept Life Sci, Seoul 04763, South Korea
[2] Hanyang Univ, Nat Sci Inst, Seoul 04763, South Korea
[3] Hanyang Univ, Hanyang Inst Biosci & Biotechnol, Seoul 04763, South Korea
基金
新加坡国家研究基金会;
关键词
DRUG-RESISTANCE; CELL-SURVIVAL; STEM-CELLS; GROWTH; METASTASIS; INHIBITION; ACTIVATION; TRANSITION; PATHWAY; GENES;
D O I
10.1093/carcin/bgae013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cysteine-rich angiogenic inducer 61 (CYR61) is a protein from the CCN family of matricellular proteins that play diverse regulatory roles in the extracellular matrix. CYR61 is involved in cell adhesion, migration, proliferation, differentiation, apoptosis, and senescence. Here, we show that CYR61 induces chemoresistance in triple-negative breast cancer (TNBC). We observed that CYR61 is overexpressed in TNBC patients, and CYR61 expression correlates negatively with the survival of patients who receive chemotherapy. CYR61 knockdown reduced cell migration, sphere formation and the cancer stem cell (CSC) population and increased the chemosensitivity of TNBC cells. Mechanistically, CYR61 activated Wnt/beta-catenin signaling and increased survivin expression, which are associated with chemoresistance, the epithelial-mesenchymal transition, and CSC-like phenotypes. Altogether, our study demonstrates a novel function of CYR61 in chemotherapy resistance in breast cancer. Our results demonstrated that CYR61 is overexpressed in TNBC and that CYR61 upregulates survivin expression through activation of Wnt/beta-catenin signaling, leading to an aggressive phenotype of TNBC including chemoresistance. Graphical Abstract
引用
收藏
页码:510 / 519
页数:10
相关论文
共 50 条
  • [41] Triple-Negative Breast Cancer
    Hudis, Clifford A.
    CANCER JOURNAL, 2010, 16 (01): : 10 - 11
  • [42] Triple-Negative Breast Cancer
    Quyen D. Chu
    King, Tari
    Hurd, Thelma
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2012, 2012
  • [43] Triple-negative breast cancer
    Chacon, Reinaldo D.
    Costanzo, Maria V.
    BREAST CANCER RESEARCH, 2010, 12
  • [44] Triple-negative breast cancer
    Stockmans, Gert
    Deraedt, Karen
    Wildiers, Hans
    Moerman, Philippe
    Paridaens, Robert
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 614 - 620
  • [45] Triple-Negative Breast Cancer
    Foulkes, William D.
    Smith, Ian E.
    Reis-Filho, Jorge S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20): : 1938 - 1948
  • [46] Alternative Splicing of Cyr61 Is Regulated by Hypoxia and Significantly Changed in Breast Cancer
    Hirschfeld, Marc
    zur Hausen, Axel
    Bettendorf, Herta
    Jaeger, Markus
    Stickeler, Elmar
    CANCER RESEARCH, 2009, 69 (05) : 2082 - 2090
  • [47] Triple-negative breast cancer
    Bartsch R.
    Ziebermayr R.
    Zielinski C.C.
    Steger G.G.
    Wiener Medizinische Wochenschrift, 2010, 160 (7-8) : 174 - 181
  • [48] Triple-Negative Breast Cancer
    Liedtke, Cornelia
    Schmutzler, Rita
    Schneeweiss, Andreas
    Loibl, Sybille
    Thill, Marc
    Heitz, Florian
    BREAST CARE, 2010, 5 (05) : 359 - 363
  • [49] Triple-negative breast cancer
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2020, 120 (08) : 22 - 23
  • [50] Triple-negative breast cancer
    Reinaldo D Chacón
    María V Costanzo
    Breast Cancer Research, 12